While we have been talking about the potential for a Licencing...

While we have been talking about the potential for a Licencing Agreement with Genentech in the antimicrobial space, DS is perfectly correct in his 27 August post that "oncology is still the main game and iMYCs the key".

The photograph posted by SoT of that handshake with Don O'Sullivan, however, reminded me of a conversation with our former CEO in the past 18 months. He said, in reference to iMYCs, that the Genentech collaboration had provided access to the right people. So what, you say and anyway that was over a year ago.

Relationships develop over time and in biotech terms, it usually takes a lot of time.

Don O'Sullivan, speaking at BIO-Europe 2015, said that the antibody-antibiotic conjugate platform developed by Genentech leveraged a lot of work from their oncology ADC platform. It would be altogether unsurprising that its not all one way traffic. Undoubtedly, breakthroughs in the antibody-antibiotic platform could be leveraged back to the oncology gurus.

So, how does Phylogica benefit from this exchange of information and technology. Often, its not just the science its about knowing the right people.